Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
|
|
Citius Pharmaceuticals, Inc. (CTXR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/15/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/31/2023 |
8-K
| Quarterly results |
| 05/12/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"FORM OF WARRANT ISSUED MAY 8, 2023",
"FORM OF PLACEMENT AGENT WARRANT ISSUED MAY 8, 2023",
"OPINION OF WYRICK ROBBINS YATES & PONTON, LLP",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of May 3, 2023, between Citius Pharmaceuticals, Inc., a Nevada corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act of 1933, as amended , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Compan...",
"Citius Pharmaceuticals Announces $15 Million Registered Direct Offering",
"Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering" |
|
| 05/05/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 04/24/2023 |
8-K
| Quarterly results |
| 04/03/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/10/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/10/2023 |
8-K
| Quarterly results |
| 02/10/2023 |
10-Q
| Quarterly Report for the period ended December 31, 2022 |
| 02/07/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 12/22/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update $41.7 million in cash and cash equivalents as of September 30, 2022; extends runway through December 2023 Mino-Lok® Phase 3 trial closer to completion with 169 patients recruited, 72 failure events and 17 patients in active treatment or pending data review I/ONTAK BLA accepted for filing by the FDA; updated PDUFA target action date is July 28, 2023 Halo-Lido Phase 2b trial progressed; data readout expected 2H 2023 Multiple value-driving catalysts anticipated in 2023, including a potential drug approval and two trial completions CRANFORD, N.J., December 22, 2022 -- Citius Pharmaceuticals, Inc. , a late-stage biopharmaceutical company dedicated to the development and commercialization of..." |
|
| 12/22/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 12/22/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 12/22/2022 |
10-K
| Annual Report for the period ended September 30, 2022 |
| 12/01/2022 |
8-K
| Quarterly results |
| 11/21/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/28/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/22/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/08/2022 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 07/12/2022 |
8-K
| Quarterly results |
| 07/08/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 05/25/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/06/2022 |
8-K
| Quarterly results |
| 04/26/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 04/13/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/06/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK for the Treatment of Persistent or Recurrent Cutaneous T-Cell Lymphoma in Support of BLA Submission CRANFORD, N.J., April 6, 2022 -- Citius Pharmaceuticals, Inc. , a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products in oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies, today reported topline results from the pivotal Phase 3 trial of I/ONTAK , an engineered IL-2-diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . The topline results for I/ONTAK , a purified and more bioactive formulation ..." |
|
|
|
|